269 related articles for article (PubMed ID: 22220518)
21. Prevalence of known prognostic factors in female breast carcinoma including oestrogen receptor, progesterone receptor and Her-2/neu status--a study in a tertiary care centre.
Chakrabarti S; Karmakar R; Barui G; Maity PK; Bandyopadhyay A; Roy A
J Indian Med Assoc; 2012 Dec; 110(12):876-9. PubMed ID: 23936949
[TBL] [Abstract][Full Text] [Related]
22. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
Sheikh UN; Cohen C; Siddiqui MT
Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
[TBL] [Abstract][Full Text] [Related]
23. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2.
Cano G; Milanezi F; Leitão D; Ricardo S; Brito MJ; Schmitt FC
Diagn Cytopathol; 2003 Oct; 29(4):207-11. PubMed ID: 14506673
[TBL] [Abstract][Full Text] [Related]
24. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
[TBL] [Abstract][Full Text] [Related]
25. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination.
Pegolo E; Machin P; Riosa F; Bassini A; Deroma L; Di Loreto C
Cancer Cytopathol; 2012 Jun; 120(3):196-205. PubMed ID: 22298467
[TBL] [Abstract][Full Text] [Related]
26. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
[TBL] [Abstract][Full Text] [Related]
27. Immunocytochemical evaluation of estrogen receptor on archival Papanicolaou-stained fine-needle aspirate smears.
Krishnamurthy S; Dimashkieh H; Patel S; Sneige N
Diagn Cytopathol; 2003 Dec; 29(6):309-14. PubMed ID: 14648786
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.
Hanley KZ; Birdsong GG; Cohen C; Siddiqui MT
Cancer; 2009 Aug; 117(4):279-88. PubMed ID: 19551847
[TBL] [Abstract][Full Text] [Related]
29. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry.
Radhika K; Prayaga AK
Indian J Cancer; 2010; 47(2):148-50. PubMed ID: 20448377
[TBL] [Abstract][Full Text] [Related]
30. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
31. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
32. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of steroid receptors and HER 2/neu in breast cancer biopsies of women living in Puerto Rico.
Colón E; Reyes JS; González Keelan C; Climent-Peris C
P R Health Sci J; 2002 Dec; 21(4):299-303. PubMed ID: 12572236
[TBL] [Abstract][Full Text] [Related]
34. [Correlation between receptor status and results of treatment in endometrial carcinoma].
Baĭnazarova AA; Iskakova ZhK
Vopr Onkol; 2006; 52(6):654-8. PubMed ID: 17338243
[TBL] [Abstract][Full Text] [Related]
35. A reliable method of demonstrating HER-2/neu, estrogen receptors, and progesterone receptors on routinely processed cytologic material.
McKee GT; Tambouret RH; Finkelstein D
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):352-7. PubMed ID: 11759063
[TBL] [Abstract][Full Text] [Related]
36. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
[TBL] [Abstract][Full Text] [Related]
37. [Detection of HER-2/neu in breast carcinoma].
Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
[TBL] [Abstract][Full Text] [Related]
38. Immunocytochemical determination of estrogen and progesterone receptors on 219 fine-needle aspirates of breast cancer. A prospective study.
Marrazzo A; Taormina P; Leonardi P; Lupo F; Filosto S
Anticancer Res; 1995; 15(2):521-6. PubMed ID: 7763033
[TBL] [Abstract][Full Text] [Related]
39. Comparison of HER-2/neu, ER and PCNA expression in premenopausal and postmenopausal patients with breast carcinoma.
Zheng W; Zheng J; Ma L; Meng F; Huang L; Ma D
APMIS; 2005 Mar; 113(3):175-81. PubMed ID: 15799760
[TBL] [Abstract][Full Text] [Related]
40. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
